company background image
ICAD

iCAD NasdaqCM:ICAD Stock Report

Last Price

US$1.55

Market Cap

US$41.4m

7D

19.2%

1Y

-13.9%

Updated

29 Nov, 2023

Data

Company Financials +

ICAD Stock Overview

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States.

ICAD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

iCAD, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for iCAD
Historical stock prices
Current Share PriceUS$1.55
52 Week HighUS$3.97
52 Week LowUS$1.05
Beta1.42
1 Month Change15.67%
3 Month Change-32.02%
1 Year Change-13.89%
3 Year Change-84.17%
5 Year Change-62.01%
Change since IPO-96.94%

Recent News & Updates

Recent updates

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Sep 27
We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Jun 21
We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

Feb 10
Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

Nov 09
Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

Jun 24
Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans

Feb 23
iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans

iCAD: Downside Seems Limited

Jan 16

iCAD, Inc. (NASDAQ:ICAD) Analysts Just Cut Their EPS Forecasts Substantially

Jan 06
iCAD, Inc. (NASDAQ:ICAD) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why We're Not Too Worried About iCAD's (NASDAQ:ICAD) Cash Burn Situation

Nov 11
Here's Why We're Not Too Worried About iCAD's (NASDAQ:ICAD) Cash Burn Situation

Is It Too Late To Consider Buying iCAD, Inc. (NASDAQ:ICAD)?

Jun 25
Is It Too Late To Consider Buying iCAD, Inc. (NASDAQ:ICAD)?

iCAD inks global distribution agreement with Sectra

Jun 08

Is iCAD (NASDAQ:ICAD) Weighed On By Its Debt Load?

May 31
Is iCAD (NASDAQ:ICAD) Weighed On By Its Debt Load?

Is iCAD, Inc. (NASDAQ:ICAD) Trading At A 39% Discount?

May 16
Is iCAD, Inc. (NASDAQ:ICAD) Trading At A 39% Discount?

iCAD, Inc. (NASDAQ:ICAD): Is Breakeven Near?

Mar 19
iCAD, Inc. (NASDAQ:ICAD): Is Breakeven Near?

Is iCAD, Inc.'s (NASDAQ:ICAD) Shareholder Ownership Skewed Towards Insiders?

Mar 02
Is iCAD, Inc.'s (NASDAQ:ICAD) Shareholder Ownership Skewed Towards Insiders?

Shareholder Returns

ICADUS Healthcare ServicesUS Market
7D19.2%-0.7%0.09%
1Y-13.9%-9.7%10.4%

Return vs Industry: ICAD underperformed the US Healthcare Services industry which returned -5.5% over the past year.

Return vs Market: ICAD underperformed the US Market which returned 13.3% over the past year.

Price Volatility

Is ICAD's price volatile compared to industry and market?
ICAD volatility
ICAD Average Weekly Movement10.0%
Healthcare Services Industry Average Movement8.9%
Market Average Movement6.0%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.9%

Stable Share Price: ICAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ICAD's weekly volatility has decreased from 16% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1984109Dana Brownhttps://www.icadmed.com

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company’s breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography.

iCAD, Inc. Fundamentals Summary

How do iCAD's earnings and revenue compare to its market cap?
ICAD fundamental statistics
Market CapUS$41.37m
Earnings (TTM)-US$12.54m
Revenue (TTM)US$25.36m

1.6x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ICAD income statement (TTM)
RevenueUS$25.36m
Cost of RevenueUS$7.72m
Gross ProfitUS$17.64m
Other ExpensesUS$30.18m
Earnings-US$12.54m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin69.57%
Net Profit Margin-49.45%
Debt/Equity Ratio0%

How did ICAD perform over the long term?

See historical performance and comparison